Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles

NCTNCT00542126 (opens ClinicalTrials.gov in a new tab)Other idGnRHFETsupport.CTIL
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
Not stated
Sponsor
Shaare Zedek Medical Center · Other
Design
Randomized · Open label (no masking)
Countries
1 country

Israel

Start
Dec 2007
Primary completion
Not stated
Completion
Sept 2009 (estimated)
First posted
10 Oct 2007 (estimated)
Last update posted
10 Oct 2007 (estimated)
Conditions
Pregnancy Rate

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2007200820092010
  1. N/A

    Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles

    NCT00542126

    Dec 2007 to est. Sept 2009

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro Fertilization treatment, but may have a negative effect on uterine function and contribute the fact that the majority of preembryos placed in the uterus fail to implant. Several medical agents were shown to be beneficial when given in the luteal phase of an IVF cycle, but the optimal regimen has not been yet determined. In 2006, a European group reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle significantly improved pregnancy and delivery rates. It is not known whether this positive effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.

Interventions

  • Decapeptyl 0.1 mg after embryo transferDrug

Arms2

  • Active comparator

    1

    GnRH analog administration following embryo transfer

  • No intervention

    2

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. pregnancy and delivery rates

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2006

6 results

Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.

Tesarik et al. 2006Human reproduction (Oxford, England)cited by 89

PMID 16926261DOI 10.1093/humrep/del173PUB-16926261

Full text at the publisher6 results
Publisher pageSee results (6)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 18 Years up to 38 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: IVF patients transfer of a minimum of two medium-quality thawed embryos in IVF Exclusion Criteria: 1. Two or more fresh IVF embryo transfer or three or more thawed embryos transfer with no pregnancy. 2. maximal endometrial thickness \< 6 mm or intracavitary fluid at the time of embryo transfer on previous cycles 3. Untreated hydrosalpinges 4. intracavitary mass 5. submucous myoma 6. known allergy to one of medical agents used in the study

PepBank is a research reference. Talk to a doctor before you use any peptide.